Clinical research organization Clinipace Worldwide, which raised $13 million and made an acquisition in September, has gone back to investors to raise another $9 million, according to an SEC filing.

The filing, made Oct. 25, says Clinipace raised $9,060,000 – the total amount it sought to sell.

The funding includes a mixture of equity, debt and options, the company said.

Last month, Clinipace bought California CRO Paragon Biomedical.

Financial terms between the two privately-held companies were not disclosed but Clinipace closed on a $13 million in new financing , according to securities filings. Clinipace said the definitive merger agreement is to acquire all outstanding shares of Paragon, a CRO headquartered in Irvine, Calif. that also has operations in the United Kingdom and India.

Clinipace was founded in 2003 as a “digital CRO” providing clinical trial services through its proprietary software. The company has turned to acquisitions as a way to expand its range of services as well as its global footprint. Clinipace’s first acquisition was the 2009 deal for Worldwide Clinical Trials, a Kansas CRO with experience in oncology and a presence in Latin America. Following the acquisition Clinipace modified its name to Clinipace Worldwide.

Clinipace has been forthright about its global expansion plans. When the CRO closed on a $15 million series C round last year led by Morgan Stanley Expansion Capital, the company said that the funding would support the firm’s global expansion.

Clinipace last year acquired Colorado consulting firm Regulus Pharmaceutical Consulting. That deal did not bring new international territory to Clinipace but it did bring regulatory expertise. Shortly after bringing Regulus into the fold, Clinipace acquired PFC Pharma Focus, a CRO in Switzerland that also has offices in Germany, Israel and India.